Les nanoémulsions huile dans eau (H/E) sont utilisées depuis plus de 50 ans en clinique humaine comme source de lipides en nutrition parentérale. Si cette dernière décennie a vu émerger la mise à profit de cette forme comme véhicule de substances actives lipophiles, l’utilisation des nanoémulsions comme vecteur d'agents thérapeutique ou diagnostique reste encore sous-exploitée. L’objectif de cette thèse a été le développement d'une plateforme de nanoémulsions comme vecteur alternatif aux nanosystèmes classiquement utilisés. Deux applications ont été visées : le diagnostic de la plaque vulnérable d'athérosclérose et le traitement de la maladie de Parkinson. Les nanoémulsions ont été fonctionnalisées avec des anticorps humanisés dirigés contre l’athérome et chargées avec des particules magnétiques pour servir d’agent de contraste moléculaire pour l’imagerie par résonance magnétique (IRM) et pour une nouvelle technique : l’imagerie par particules magnétique (IPM). L'efficacité du nanosystème pour le ciblage de la plaque a été démontré sur des souris athéromateuses. L’inclusion de chromophores lipophiles originaux et ultrabrillants ainsi que la possibilité d'incorporer des substances actives ont permis d’ouvrir la voie vers le développement de formulations multimodales et théranostiques. Les nanoémulsions thérapeutiques contre Parkinson ont été développées pour rétablir le pH lysosomal des neurones dopaminergiques par l'encapsulation d'un polymère (PLGA). Ce défaut d’acidification favorise la mort cellulaire par l’accumulation de déchets dans les neurones. La formulation a été optimisée pour le passage intracérébral par voie intraveineuse ou intranasale. Les résultats montrent un passage cérébral in vivo par voie intraveineuse avec une confirmation in vitro de la régénération du pH. Les perspectives de ce travail sont la poursuite de la plateforme et l'ouverture vers de nouvelles applications comme l'hyperthermie magnétique dans les cancers. / Oil in water (O/W) nanoemulsions have been used for over 50 years in human clinics as a lipids source in parenteral nutrition. Even if nanoemulsions have recently emerged as vehicles for lipophilic active pharmaceutical ingredient (API) their use as a therapeutic or diagnostic agent is still under-exploited. The objective of this Ph.D thesis was to develop an nanoemulsions platform as an alternative to conventionally used nanosystems. In this work, 2 applications have been studied: the diagnosis of vulnerable plaque in atherosclerosis, and the treatment of Parkinson's disease. Nanoemulsions have been functionalized with humanized antibody targeting atheroma and loaded with magnetic particles as molecular contrast agents for magnetic resonance imaging (MRI) and an emerging technique: magnetic particle imaging (MPI). The successful plaque targeting has been demonstrated in atheromatous mice. The inclusion of original and ultra-bright lipophilic chromophores as well as the loading of API have paved the way to the development of multimodal and theranostic formulations. Therapeutic nanoemulsions against Parkinson’s disease have been developed to restore lysosomal pH of dopaminergic neurons with acidic polymer (PLGA). Acidification dysfunction leads to cell death due to the accumulation of waste inside neurons. The formulation has been optimized for brain delivery through intravenous or intranasal administration. The results show brain delivery in vivo trough intravenous injection associated with a pH rescue in vitro. The perspectives will focus on optimizing this platform and use it for new applications such as magnetic hyperthermia in cancers.

Iron oxide nanoparticles are of great interest as contrast agents for research and potentially clinical molecular magnetic resonance imaging (MRI). Biochemically modifying the surface coatings of the particles with proteins and polysaccharides enhances their utility by improving cell receptor specificity, increasing uptake for cell labeling and adding therapeutic molecules. Together with the high contrast they produce in MR images, these characteristics promise an expanding role for iron oxide nanoparticles and molecular MR imaging for studying, diagnosing and treating diseases at the molecular level. However, these contrast agents produce areas of signal loss with traditional MRI sequences that are not specific to the nanoparticles and cannot easily quantify the contrast agent concentration. With the expanding role of iron oxide nanoparticles in molecular imaging, new methods are needed to produce a quantitative contrast that is specific to the iron oxide nanoparticle. This dissertation presents a new method for detecting and quantifying iron oxide nanoparticles using an adiabatic preparation pulse and the failure of the adiabatic condition for spins diffusing near the particles. In the first aim, the theoretical foundation of the work is presented, and a Monte Carlo simulation supporting the proposed mechanism of the contrast is described. Adiabatic pulse prepared imaging sequences are also developed for imaging at 3 Tesla and 9.4 Tesla to highlight the translational potential of the approach for clinical examinations and scientific research, and the linear correlation of the contrast with iron concentration ideal for quantification is presented. Further, the physical characteristics of the nanoparticles and the parameters of the MRI sequence are modified to characterize the approach. In the second aim, the contrast is characterized in more realistic phantoms and in vitro, and a method to more accurately quantify nanoparticle concentration in the presence of magnetization transfer is presented. Finally, accelerated imaging methods are implemented to acquire the adiabatic contrast in a time compatible with in vivo imaging, and the technique is evaluated in an in vivo model of quantitative iron oxide nanoparticle imaging. Together, these aims present a method using an adiabatic preparation pulse to generate an MR contrast based on the microscopic magnetic field gradients surrounding the iron oxide nanoparticles that is suitable for in vivo quantitative, molecular imaging.

No description available.